Conquer the world’s most intractable diseases
Founded by pioneers in synthetic biology from leading institutions, Radar Therapeutics leverages the explosion in single-cell transcriptomic data, advances in our understanding of RNA-editing enzymes, and simple, elegant logic gates to make “smart” mRNAs.
WebsiteRadar Therapeutics is recognized among the 2025 BioInnovation Institute & Science Prize for Innovation winners for its work on programmable medicines and RNA sensing.
Radar Therapeutics raised an oversubscribed $13.4 million seed round to advance smart programmable medicines that use molecular RNA sensors to target therapeutic activity.
Radar Therapeutics was selected alongside Nosis Bio and ResVita Bio for an AbbVie-sponsored Golden Ticket, providing a year of free access to Bakar Labs facilities.
National Hispanic Institute named Radar Therapeutics co-founder and CEO Sophia Lugo its 2024 Person of the Year, recognizing her leadership journey and work in biotechnology.
Radar Therapeutics received the inaugural Amgen Bakar Labs Diversity, Inclusion & Belonging Award, recognizing the company’s commitment to building an inclusive biotech organization.
We invest in brilliant founders building transformational platforms through breakthrough technologies at Pre-Seed stage.
